In the previous study, we demonstrated that exposure to extremely low frequency magnetic fields (ELF-MF) increases striatal dopamine levels , and that ELF-MF induces hyperlocomotor activity via dopaminergic D1 receptor stimulation (Shin et al., 2007) .
Little is known about the role of magnetic fields in modulations of AP-1 transcription factors in vivo, although magnetic fieldsinduced up-regulations in AP-1 transcription factors have demonstrated in vitro (Lin et al., 1998; Hirai et al., 2002) . Since FRA is the most important factor of the AP-1 modulation of genes necessary for neuronal adaptation (Pennypacker et al., 1995; Bing et al., 1996; Bing et al., 1997b) , we examined FRAimmunoreactivity (FRA-IR) in the striatum and nucleus accumbens (striatal complex) after ELF-MF exposure, and we evaluated whether dopaminergic receptors are involved in the induction of FRA by applying dopaminergic D1 receptor antagonist, SCH 233390 and dopaminergic D2 receptor antagonist, sulpiride. Unexpectedly, we observed that FRA-IR lasted for at least 1 year after final exposure to ELF-MF. This longlasting FRA-IR requires activation of dopaminergic D1 receptor.
MATERIALS AND METHODS

Animals and treatments
All mice were handled in accordance with the US National Institute of Health guidelines for the humane care of laboratory animals and the Institutional Animal Care and Use Committee of Kangwon National University. Male adult C57BL/6 mice (Orient Bio Inc., Charles River Technology, Gapyung-Gun, Gyeonggi-Do, Korea), weighing 25±2 g, were maintained on a 12:12 h light:dark cycle, with food and water available ad libitum. The ambient conditions were maintained at 20±2°C. Mice were adapted to these conditions for 2 weeks before the experiments.
The ELF-MF was generated with three Helmholtz coils, set parallel to each other, in a wooden frame Shin et al., 2007) . The ELF-MF consisted of 60-Hz time-varying fields and the magnetic flux density was 0.3 or 2.4 mT. Animals were exposed to ELF-MF for 1 h/day for fourteen days. As seven days' exposure to ELF-MF was not fully enough for locomotor stimulation (Shin et al., 2007) , we extended exposure period by fourteen days in this study. Thirty minutes before the animals were exposed to ELF-MF, mice were treated with SCH23390 hydrochloride (SCH, D1 antagonist; Tocris Co., Ellisville, MO, USA) at 0.03 or 0.1 mg/kg, i.p. or (RS)-(±) sulpiride (Sulp, D2 antagonist; Tocris Co.) at 10 or 20 mg/kg, i.p. (Shin et al., 2007) . Locomotor activity was measured 0 hour, 1 day, 1 week, 3 months or 1 year after the final ELF-MF exposure using an automated video-tracking system (Noldus Information Technology, Wagenin, The Netherlands). Eight test boxes (40×40×30 cm high) were operated simultaneously by a computer. Animals were studied individually during locomotion in the test box. A printout for each session showed the pattern of ambulatory movements in the test box. The distance traveled (in cm) was analyzed for 30 min. Data were collected and analyzed between 9:00 and 17:00 h. Animals were sacrificed for immunohistochemical analyses 90 min after measurement of locomotor activity.
Immunohistochemistry
Sections containing the nucleus accumbens and striatum were processed for FRA immunohistochemistry. Prior to incubation with the primary antibody, sections were preincubated in PBS containing 0.2% Triton X-100 and 4% normal goat serum for 20 min. After 48-h incubation with the primary antibody against FRA (1 : 2,000, Young et al., 1991; Bing et al., 1996; Kim et al., 2001 ) at 4°C, sections were incubated with the secondary biotinylated anti-rabbit IgG (1 : 1,000; Vector Laboratories, Inc., Burlingame, CA, USA) for 1 h, and immersed in avidin-biotinperoxidase complex (ABC Kits; Vector Laboratories, Inc.) for 1 h. 3,3'-Diaminobenzidine was used as the chromogen. Digital images of FRA-immunoreactive neurons were acquired on an Olympus microscope (Tokyo, Japan), using an attached digital microscope camera (Olympus, Tokyo, Japan) and a personal 
Statistics
Data were analyzed using analysis of variance (ANOVA) and Post-hoc Fisher's PLSD test was followed for the comparison among groups. A p value less than 0.05 was deemed to be statistically significant.
RESULTS
Experimental schedules are shown in Fig. 1 . Control mice showed a basal locomotor activity (Fig. 2) . Locomotor activity was significantly increased immediately after the final exposure to ELF-MF in a field intensity-dependent manner, and it remains elevated 1 week later (0 hour and 1 day: Saline+0. However, dopaminergic D2 receptor antagonist, sulpiride did not significantly alter hyperlocomotor activity induced by ELF-MF (Fig. 2) .
FRA-immunoreactive cells were barely observed in the striatal complex of the control (Fig. 3 and 4) . Repeated exposure to ELF-MF significantly increased FRA-IR in the striatal complex 2 hours after the final exposure in a field intensity-dependent manner, and this FRA induction lasted for 1 year (both of striatum and nucleus accumbens at 2 hours, 1 day, 1week, 3 months and 1 year: Saline+0. 3 Experimental schedule for evaluating effects of repeated exposure to extremely low frequency magnetic fields (ELF-MF) on the locomotor activity and fos-related antigen-immunoreactivity (FRA-IR) in the striatum and nucleus accumbens (striatal complex) of the mice. Animals were exposed to ELF-MF (0.3 or 2.4 mT, 1 hour/day) for consecutive 14 days. Thirty minutes before each exposure to ELF-MF, mice were treated with SCH23390 hydrochloride (a dopaminergic D1 antagonist; 0.03 or 0.1 mg/kg, i.p.) or sulpiride (a dopaminergic D2 antagonist; 10 or 20 mg/kg, i.p.). Locomotor activity was measured 0 hour, 1 day, 1 week, 3 months and 1 year after the final ELF-MF exposure using an automated video-tracking system. Mice were sacrificed for immunocytochemical evaluation 90 min after the measurement of locomotor activity. *SCH23390 (a dopaminergic D1 antagonist; 0.03 or 0.1 mg/kg, i.p.) or Sulpiride (a dopaminergic D2 antagonist; 10 or 20 mg/kg, i.p.) was injected 30 min prior to ELF-MF exposure. § Behavioral evaluation followed by immunocytochemical study. (Fig. 3 and 4) . (Bing et al, 1997b; Kim et al., 1998 ). Enkephalin and dynorphin, which are derived from proenkephalin precursor and prodynorphin precursor, respectively, have been suggested to play an important role in the neuroadaptive responses related to behavioral sensitization, drug reward, drug withdrawal, or recovery of motor function via modulating post-synaptic dopaminergic receptor sensitivity or pre-synaptic dopamine release (Steiner and Gerfen, 1998; Bruijnzeel, 2009 ). Moreover, it has been reported that exposure to magnetic fields increases prodynorphin gene expression (Ventura et al., 2000) and regulates the activity of opioid receptors (Thomas et al., 1997) . Therefore, it may be possible that proenkephalin-and prodynorphin-genes may be involved in the neuroadaptive responses mediated by long-term FRA expression in response to ELF-MF, although the role and physiological significance of the long-term expression of FRA induced by ELF-MF remain to be further clarified.
In the present study, ELF-MF-induced long-lasting FRA expression in the striatal complex was attenuated by SCH23390, a dopaminergic D1 antagonist, but not by sulpiride, a dopaminergic D2 antagonist, suggesting that ELF-MF induces long-lasting FRA-IR via stimulation of dopaminergic D1 receptor. These results are in line with previous findings showing that direct stimulation of D1 receptor with specific agonist (Wirtshafter, 2007) or indirect stimulation of D1 receptor with psychostimulants (Young et al., 1991; Bronstein et al., 1996; Zhang et al., 2002) augments FRA expression in the striatal complex. Especially, it has been suggested that dopaminergic D1 receptor-mediated adenylate cyclase signaling pathway, but not phospholipace C pathway, is necessary for inducing FRA in the striatum (Wirtshafter, 2007 (Janać et al., 2009 ), rats were fully exposed to ELF-MF for up to 7 days, whereas mice were exposed to ELF-MF for consecutive 14 days in our present study. Since it has been suggested that ELF-MFinduced change in neuronal activity and behaviors may be affected by exposing schedule (Lyskov et al., 1993) , it requires further study to achieve better understanding on the discrepancy between Janać et al. (2009) and current finding. In the behavioral evaluation, locomotor activity was increased after repeated exposure to ELF-MF, and it returned near control level 3 months later. ELF-MF-induced hyperlocomotor activity was also attenuated by dopaminergic D1 antagonist, SCH23390. Although locomotor activity can not fully support time-dependent pattern in FRA in the striatal complex, we raise the possibility that FRA expression modulates, at least in part, behavioral responses to repeated ELF-MF exposure. It has been reported that induction of 35-kDa FRA is accompanied with behavioral changes during repeated treatment with psychostimulants, such as cocaine (Rosen et al., 1994; Hiroi et al., 1997) or amphetamine (Turgeon et al., 1997) . Striatal expression of 35-kDa FRA and hyperlocomotor activity after repeated treatment with cocaine or amphetamine have shown to be more pronounced than those after single injection (Hiroi et al., 1997; Turgeon et al., 1997) , suggesting that 35-kDa FRA plays a key role in repeated neuronal stimulation. In addition, Hsieh et al. (2002) reported that elevated 35-kDa FRA expression, but not c-Fos expression, is sustained for at least 40 days after withdrawal from repeated amphetamine administration, while locomotor activity returned near control level 10 days after withdrawal, suggesting that 35-kDa FRA plays a certain role in neurobehavioral adaptation.
Our results suggest that repeated exposure to ELF-MF induces prolonged locomotor stimulation and long-term expression of FRA in the striatal complex via stimulation of dopaminergic D1 receptor. Finally, we raise the possibility that ELF-MFmediated dopaminergic activations can be one of the therapeutic interventions for improving Parkinson' s symptoms.
